Hepatic ischemia/reperfusion (I/R) is a major challenge for liver surgery and specific severe conditions of chronic liver disease. Current surgical and pharmacological strategies are limited to improve liver function after hepatic I/R injury. Thus, an in-depth understanding of the liver I/R mechanism is pivotal to develop new therapeutic methods. The cellular repressor of E1A-stimulated genes (Creg), a key regulator of cellular proliferation, exerts protective roles in cardiovascular diseases and participates in lipid accumulation and inflammatory response in the liver. However, the role of Creg in hepatic I/R remains largely unknown. A genetic engineering technique was used to explore the function of Creg in hepatic I/R injury. Hepatocyte-specific Creg knockout (Creg
remains a severe complication that increases the probability of postoperative mortality, morbidity, and graft failure. (3, 4) Accumulating evidence indicates that the principal mechanism underlying the pathophysiological process of liver I/R injury is cell death and inflammation. (5) During the ischemic phase, hepatocytes are the major parenchymal cells that are sensitive to metabolic disturbance, resulting from a lack of oxygen supply, glycogen consumption, and adenosine triphosphate exhaustion elicited by I/R-related liver injury, which initiates cell death. During the reperfusion period, the stressed and dying hepatocytes release damage-associated molecular patterns, which further contribute to the activation of innate immune signaling pathways and trigger the pro-inflammatory response. These events together with reoxygenation can, in turn, result in severe oxidative stress and necroapoptosis, contributing to further cell death. (6) Thus, identifying effective therapeutic approaches and simultaneously targeting cell death and innate immune system activation of hepatic I/R injury to interrupt this vicious cycle between cell death and pro-inflammatory response are clinically important for ameliorating I/R-related liver damage. Interestingly, mitogen-activated protein kinase (MAPK) signaling mediates both cell death and inflammation during liver I/R damage. (7) Therefore, targeting these regulators may potentially identify new effective pharmacological interventions in I/Rrelated liver damage in the clinic.
Cellular repressor of E1A-stimulated genes (Creg) was originally cloned from a HeLa cell line complementary DNA (cDNA) library and has been identified as a key regulator to inhibit cellular proliferation and antagonize E1A-mediated cellular transformation. (8) Since its discovery, most previous studies on Creg have focused on its critical roles in the cardiovascular pathophysiology process, including cardiac hypertrophy, (9) atherosclerosis, (10) and myocardial infarction. (11) The participation of Creg in these cardiovascular diseases is dependent primarily on its capacity to attenuate inflammation, activate autophagy, (10) and inhibit the cell death of endothelial and vascular smooth muscle cells by regulating MAPK signaling. (12, 13) Interestingly, Creg also exhibits protective properties against heart injury induced by I/R insult through autophagy and anti-apoptosis. (14) A recent study also suggested that Creg is a suppressor of hepatic steatosis and metabolic disorders through its interaction with MAPK/apoptosis signalregulating kinase 1 (ASK1)-c-Jun N-terminal kinase 1 ( JNK1) signaling. (15) Considering the regulatory effects of Creg on cardiovascular cellular events, in particular of inflammation and cell death, which also directly correlate with the progression of hepatic I/R injury, and the characteristics of Creg in regulating MAPK signaling, we hypothesized that Creg prominently participates in the progression of hepatic I/Rinduced liver injury. Nevertheless, in the liver, Creg was only reported to be involved in lipid accumulation and inflammatory response, (15) whereas its potential role in liver I/R injury remains unknown.
To address this hypothesis, we examined hepatocyte-specific Creg knockout (Creg
ΔHep
) and transgenic (HTG) mice to evaluate the potential role and underlying mechanisms of Creg in hepatic I/R injury. Together, our data provide evidence of the essential and TAK1-dependent characteristics of Creg in hepatic I/R injury. 
Materials and Methods

aNIMalS
Hepatocyte-specific Creg knockout (Creg ΔHep ) mice and hepatocyte-specific Creg transgene (Creg-HTG) mice in the C57BL/6J background were generated as previously described. (15) We used albumin-Cre recombinase transgenic (TG) . All animals were housed in ventilated cages with 4 mice per cage at the SPF facility of Huazhong University of Science and Technology under a temperature-controlled environment with a 12-hour light/dark cycle and had free access to a normal chow diet (70% carbohydrate, 20% protein, and 10% fat) and water. Eight-to 10-week-old male mice weighing 24-27 g were used for further experiments. All animal care and experimental procedures were approved by the Animal Care Ministry of Health and were performed in accordance with national and EU guidelines. Animal studies were reported to be in compliance with the ARRIVE guidelines.
aNIMal tReatMeNt
For hepatic I/R surgery, mice were first anesthetized, and the portal vein, hepatic artery, and bile duct above the branching to the right lateral lobe were then occluded using a microvascular clamp. The clamp was removed after 60 minutes of partial hepatic ischemia to initiate different time points of reperfusion. At the end of the trial, liver tissues and serum were collected for further analysis. Mice subjected to the same process but without clamping of the liver served as sham animals. The specific TAK1 inhibitor, 5Z-7-oxozeaenol (5Z-7-ox; O9890-1 MG; Sigma, St. Louis, MO), (16) 
HUMaN lIVeR SaMpleS
Human I/R liver samples were obtained from subjects who had undergone liver resection surgery due to hepatocellular carcinoma or hepatic cyst. Liver biopsies from healthy donors who were unsuitable for liver transplantation for nonhepatic reasons served as control samples. Informed consent forms were voluntarily signed by all subjects or their families. Consent was obtained for all procedures relating to human samples from the Renmin Hospital of Wuhan University Review Board. All studies were performed according to the Declaration of Helsinki principles.
ISolatIoN aND tReatMeNt oF pRIMaRy HepatoCyteS
Primary hepatocytes were isolated from livers as previously described and cells with the viability above 90% were used for further experiments. (17) For the hypoxia and re-oxygenation experiments, the medium was changed to serum-free Dulbecco's modified Eagle medium (DMEM) medium, and cells were challenged to a hypoxia state (1% O 2 , 5% CO 2 , and 94% N 2 ) in a modular incubator chamber (Biospherix, Lacona, NY), followed by re-oxygenation (air/5% CO 2 ) at the indicated time points to mimic in vivo hepatic I/R injury. The cells and the related medium were collected for further experiments. Lactate dehydrogenase (LDH) Assay Kit (Promega, Madison, WI) was used to determine cell cytotoxicity, and an MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide) Cell Proliferation Assay Kit (Abnova, Jhongli, Taiwan, China) was used to assess cell viability.
SeRUM BIoCHeMIStRy aND CytoKINe aSSayS
The liver functions of mice were assayed by measuring the alanine aminotransferase (ALT) and aspartate amino-transferase (AST) levels in serum by the ADVIA 2400 Chemistry System (Siemens, Tarrytown, NY) according to the manufacturer's protocols. The inflammatory state was assessed by measuring serum cytokines by enzyme-linked immunosorbent assay (ELISA) kits (Peprotech, Rocky Hill, NJ; R&D Systems, Minneapolis, MN).
HIStologICal aND IMMUNoFlUoReSCeNCe StaININg
To assess the necrosis of the liver, hematoxylin and eosin (H&E) was performed as previously reported. (18) Paraffin sections were stained by immunofluorescence as previously described. (18) Primary antibodies against Creg (ab191909, Abcam, Cambridge, MA), CD3 (GA045204, Gent Tech), Ly6G (551459, BD Biosciences), and Mac1 (ab75476, Abcam) were used.
Cell DeatH aND pRolIFeRatIoN aSSayS
To evaluate cell death, TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining was performed using an ApopTag Plus In Situ Apoptosis Fluorescein Detection Kit (S7111, Millipore) according to the manufacturer's protocols. Immunofluorescence staining was performed to measure the cell proliferation by a proliferating cell nuclear antigen (PCNA) antibody as previously reported. (19) 
plaSMID CoNStRUCtIoN
The human Creg gene was cloned into pcD-NA5-hemagglutinin (HA)-C1 to generate pcDNA5-HA-Creg. To obtain the Creg fragments including residues 1 to 100, 137 to 220, 101 to 220, and 32 to 220, pcDNA5-HA-Creg was PCR-amplified using the primers provided in Supporting Information Table S1 . BamHI and XhoI were used to digest the products and then ligated into pcDNA5-HA-C1.
The primers TAK1-1F and TAK1-579R were used to PCR-amplify the human cDNA. To obtain pcDNA5-Flag-TAK1, BamHI and XhoI were used to digest the products and then ligated into pcD-NA5-Flag. To obtain the TAK1 fragment including residues 1 to 300, 1 to 390, 1 to 480, 301 to 579 and 391 to 579, pcDNA5-Flag-TAK1 was amplified with primers provided in Supporting Information Table S1. All plasmids were confirmed by sequencing.
IMMUNopReCIpItatIoN StUDIeS
To examine the interaction of Creg with other factors, the corresponding plasmids were transfected into L0 2 cells for 24 hours. After the hypoxia and re-oxygenation challenge, the cells were then collected and lysed with ice-cold immunoprecipitation buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCl, 5 mmol/L EDTA, 5% glycerol, 1% Triton X-100, containing a protease inhibitor cocktail [Roche]). Next, the obtained lysates were incubated with beads conjugating to the corresponding antibody at 4°C for 3 hours. The immunocomplex was collected and washed with ice-cold immunoprecipitation buffer and measured via immunoblotting with specified primary and secondary antibodies. (20) QUaNtItatIVe Real-tIMe pCR
Total mRNA was isolated from the tissues and cells by TRIzol reagent (Invitrogen) and was reverse transcribed with a high-capacity cDNA reverse transcription kit (TAKARA) according to the manufacturer's instructions. (21) The mRNA levels were quantified by quantitative PCR with SYBR Green (Roche, 04887352001). The relative mRNA levels were normalized against β-actin mRNA levels. The primers used for real-time PCR are provided in Supporting Information Table S2 .
WeSteRN BlottINg aNalySeS
Western blotting analysis was completed to measure the levels of protein expression in mouse liver tissues and cells as previously described. (22) Image Lab software was used to quantify the protein expression and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was served as the control. All antibodies used for western blotting analyses are presented in Supporting Information Table S3 .
StatIStICal aNalySIS
All data analyzed were expressed as the mean ± SEM. Differences between two groups were determined using Student two-tailed t test. When more than two groups were examined, one-way analysis of variance (ANOVA) followed by Bonferroni's post hoc analysis (assuming equal variances) or Tamhane's T2 post hoc analysis (without the assumption of equal variances) was performed. A P value < 0.05 was considered to be statistically significant. All statistical analyses were performed by SPSS software, version 19.0.
Results
Creg eXpReSSIoN leVelS aRe SIgNIFICaNtly DeCReaSeD DURINg HepatIC I/R INJURy
To analyze whether Creg is involved in I/Rinduced liver dysfunction, the expression of Creg in the livers of patients subjected to liver transplantation was first measured. We found that the protein levels of Creg in the patients' livers was significantly decreased compared with the controls (Fig. 1A) . Next, we established a mouse hepatic I/R model by exposing mice to a 60-minute portal vein blockage followed by reperfusion for indicated time periods. Mice subjected to the same procedure but without blood blockage served as sham controls. Importantly, both the protein and mRNA levels of Creg were decreased in the livers of WT mice in a time-dependent manner compared with the sham group (Fig. 1B) . Consistent with the results obtained from the livers of mice and human subjects, the decreased levels of Creg were also demonstrated in primary hepatocytes challenged by hypoxia/reoxygenation (H/R) administration an extensively applied in vitro model used to mimic the in vivo hepatic I/R process, compared with untreated controls (Fig. 1C) . Taken together, these results indicated that reduced Creg expression might be associated with hepatic I/R-induced liver injury.
HepatoCyte-SpeCIFIC Creg DeletIoN DeteRIoRateS HepatIC I/R INJURy
On the basis of the significantly reduced expression levels of Creg during hepatic I/R injury, we hypothesized a crucial functional relevance of Creg in hepatic I/R injury. Because hepatocytes are the main
FIg. 1.
Creg expression is significantly decreased during hepatic I/R injury. (A) Protein levels of Creg in liver samples from healthy people and patients exposed to liver transplantation (n = 6 in control group and n = 7 in liver transplantation group). (B) Protein and mRNA levels of Creg in the livers of mice subjected to sham treatment or ischemia for 1 hour followed by reperfusion for the indicated periods (n = 3; #P < 0.05 compared with control). (C) Protein levels of Creg in primary hepatocytes subjected to sham or H/R challenge for indicated periods (representative of three independent experiments). For (A)-(C), GAPDH/β-actin served as the loading control. All data are presented as the mean ± SD. For statistical analysis, one-way ANOVA with Tamhane's T2 post hoc analysis was used. responsible cells for cell death and the initiation of inflammation during the pathology of hepatic I/R injury, we generated hepatocyte-specific Creg deletion and overexpression mice to further examine the crucial function of Creg in hepatic I/R injury. As presented in Fig. 2A , the specific Creg deletion in hepatocytes was confirmed by western blotting analyses. At 24 hours after liver I/R challenge, considerably greater hepatic necrosis was observed in the liver sections of Creg ΔHep mice compared with Creg flox/flox controls as assessed by H&E staining (Fig. 2B ). Consistent with these findings, Creg deficiency in hepatocytes significantly enhanced the elevated levels of AST and ALT in serum induced by hepatic I/R surgery compared with Creg flox/flox control mice (Fig. 2C ). These findings demonstrated that Creg ΔHep mice were more sensitive to liver I/R injury compared with their counterparts. To further confirm the role of Creg in liver I/R injury, hepatocyte-specific Creg-HTG mice were generated (Fig. 2D) . In contrast to Creg ΔHep mice, Creg-HTG mice exhibited the opposite phenotype. Mice overexpressing Creg in hepatocytes showed attenuated hepatic necrosis (Fig. 2E ) and reduced levels of AST and ALT in serum ( Fig. 2F ) compared with NTG mice after 24 hours of reperfusion. These observations suggested that Creg plays a protective role during hepatic I/R-induced liver damage.
HepatoCyte-SpeCIFIC Creg DeletIoN pRoMoteS Cell DeatH aND SUppReSSeS Cell pRolIFeRatIoN DURINg lIVeR I/R INJURy
Liver I/R injury is a dynamic course that consists of two interrelated stages of local ischemic liver injury and inflammatory response-mediated liver damage during the reperfusion period.
(1) The cellular death observed during liver I/R insult is a remarkable characteristic of liver injury, as well as the effects of hepatocyte proliferation/regeneration on the prognosis of livers subjected to I/R injury. Thus, we examined whether CREG directly influences cell death and proliferation in hepatocytes and contributes to its protective effects on hepatic I/R injury. Immunofluorescence staining revealed that liver tissues obtained from Creg ΔHep mice exhibited more cell death (TUNELpositive) and fewer proliferating (PCNA-positive) cells compared with those of counterpart mice at 24 hours after reperfusion (Fig. 3A ) and was accompanied with decreased expression levels of the anti-apoptotic gene Bcl2 and increased levels of the apoptotic genes, Bax and Fas (Fig. 3B) . Moreover, increased expression of pro-cell death proteins (BAX and c-Casp3) and decreased anti-apoptosis protein (BCL-2) were more significantly induced in Creg
ΔHep mice compared with those in Creg flox/flox mice during I/R and H/R injury (Fig. 3C,D) . Furthermore, the liver cell proliferation genes (PCNA and Cyclin D1) in hepatocyte-specific Creg-deficient mice were also significantly suppressed compared with controls after hepatic I/R injury (Fig.  3E) . To further determine whether hepatocyte Creg directly mediated cell death in hepatic I/R injury, we isolated primary hepatocytes from hepatocyte-specific Creg deletion mice and WT counterparts and stimulated with the hypoxia condition. Consistent with the increased cell death observed in the immunofluorescence studies, the LDH levels (marker for cell death) from Creg-deleted primary hepatocytes challenged with hypoxia were much higher compared with WT primary hepatocytes. MTT assays also indicated that the proliferation of Creg-deleted primary hepatocytes was significantly inhibited under the hypoxia condition (Fig. 3F,G) . In contrast, Creg-HTG mice showed the opposite phenomenon (Fig. 3A-G) . These gainof-functional and loss-of-functional data strongly indicated that Creg in hepatocytes is a pivotal gene for cell survival and promotes cell proliferation during hepatic I/R-induced liver injury.
HepatoCyte-SpeCIFIC Creg DeletIoN WoRSeNS INFlaMMatoRy ReSpoNSeS DURINg HepatIC I/R INJURy
The inflammatory response, which initiates from the ischemic phase and persists throughout the entire process of hepatic I/R injury, is an essential factor during hepatic I/R injury (23) ; therefore, we aimed to determine whether hepatocyte-specific Creg could affect the inflammatory response in I/R-induced liver injury. Immunofluorescence staining revealed that the number of inflammatory and immune cells (Cd3 + T cells, Ly6g + neutrophils, and Mac1 + macrophages) in the liver of Creg ΔHep mice was significantly increased after subjecting the mice to liver I/R injury compared with those of their counterparts (Fig. 4A) . In contrast, Creg-HTG mice demonstrated significantly (Fig. 4C) . Consistent with findings obtained from in vivo experiments, primary hepatocytes isolated from Creg ΔHep mice challenged with hypoxia for 60 minutes and followed by re-oxygenation for 12 hours demonstrated an increased inflammatory state as evidenced by the increased expression of inflammatory cytokines (TNF-α, IL-1, and IL-6) and chemokines (MCP-1 and CXCL-1) in the medium compared with controls (Fig. 4D) . In addition, increased activation of nuclear factor (NF)-κB signaling (belonging to the innate immune signaling and responsible for the pro-inflammatory responses) was observed in Creg
ΔHep hepatocytes challenged by I/R injury or H/R treatment compared with controls (Fig. 4E,F) . In contrast, Creg overexpression resulted in an adverse phenomenon (Fig. 4A-F) . Taken together, these findings revealed the essential protective role of Creg in hepatocytes against the inflammatory response during hepatic I/R-induced liver injury.
Creg IN HepatoCyteS RegUlateS tHe taK1/JNK patHWay DURINg HepatIC I/R INJURy
The potent regulatory activity of Creg in I/Rinduced liver injury motivated studies to investigate its underlying mechanisms. Among the abundant signaling pathways, the MAPK pathway has been found to regulate both cell death and inflammation. (24) Importantly, numerous studies have reported that Creg mediates the MAPK pathway, supporting the potential function of Creg in MAPK signaling during I/R-induced liver injury. (13) , (25) Western blotting analyses demonstrated that the phosphorylation of JNK1/2, p38, ERK1/2, and MEK1/2 in liver tissues and hepatocytes was activated after I/R or H/R treatment; however, hepatocyte-specific Creg knockout mice showed only increased p-JNK1/2 and p-p38 compared with p-ERK1/2 and p-MEK1/2, and Creg-HTG mice showed decreased phosphorylation levels of p-JNK1/2 and p-p38 instead of other kinases in liver tissues after 24-hour reperfusion or in hepatocytes after 12 hours of reoxygenation (Fig. 5A,B) . Moreover, the phosphorylation levels of upstream kinases, including MKK4 and MKK7 and downstream kinases, c-JunS63 and c-JunS73, were also increased in Creg ΔHep mice and decreased in Creg-HTG mice at 24 hours of reperfusion or at 12 hours after reoxygenation (Fig. 5C,D) . The simultaneous decrease in the phosphorylation levels of MKK4 and MKK7 in Creg-HTG during liver I/R injury indicated that a potential common upstream element may exist. To further confirm the potential upstream kinases influencing Creg to stimulate the MAPK signaling pathway, the phosphorylation levels of TAK1, ASK1, and MEKK1 (mitogen-activated protein kinase kinase kinase 1) in livers or hepatocytes after I/R or H/R insult were measured by western blotting analyses. Interestingly, Creg ΔHep affected only p-TAK1, rather than p-ASK1 and p-MEKK1 in liver tissues or hepatocytes during I/R or H/R insult (Fig. 5E,F) . Together, these observations indicated that in hepatocytes, Creg inhibits the activation of p-JNK1/2 and p-p38 through TAK1 during hepatic I/R-induced liver injury. 
HepatoCyte-SpeCIFIC Creg DeletIoN eXaCeRBateS lIVeR I/R INSUlt IN a taK1-DepeNDeNt MaNNeR
To ascertain the critical role of TAK1 in Cregmediated I/R injury in vivo, we further used a specific TAK1 inhibitor, 5Z-7-ox, (26) to perform an intraperitoneal injection in Creg ΔHep mice before I/R injury. Compared with DMSO, 5Z-7-ox largely abolished the activation levels of phosphorylation of JNK, p38 and NF-κB, and inhibited IκBα degradation observed in Creg
ΔHep mice livers after 6 hours of reperfusion (Fig. 6A) . Furthermore, the TAK1 inhibitor abolished the liver function damage and inflammatory responses induced by hepatocyte-specific Creg deletion, as evidenced by reduced serum aminotransferase activity (ALT and AST) and decreased gene expression of pro-inflammatory factors (Tnfα, Il1, and Mcp1), anti-apoptotic gene Bcl2, and increased apoptotic gene Bax and cell proliferation gene PCNA in livers after challenged by I/R injury (Fig. 6B,C) and was accompanied by the decreased pro-inflammatory factors (TNF-α, IL-1β, IL-6, MCP-1, and CXCL-1) in serum (Fig. 6D) . In addition, these observations were further confirmed by in vitro experiments, in which 5Z-7-ox largely promoted cell proliferation and abolished cell death in primary hepatocytes of Creg ΔHep mice challenged by H/R insult, as evidenced by the MTT assay (cell proliferation) and LDH assay (cell death) (Fig. 6E,F) . These results indicated that TAK1 activation is required for hepatocyte-specific Creg deletion-mediated liver I/R injury.
We further examined the interaction between Creg and the response molecules in MAPK signaling (including TAK1, MKK4/7, and JNK1/2) to investigate the precise underlying mechanism. Immunoprecipitation experiments further demonstrated that Creg immunoprecipitated with TAK1 rather than other molecules (Fig. 7A) . Furthermore, co-immunoprecipitation studies showed an interaction between exogenous Creg and TAK1 (Fig. 7B) . The endogenous co-immunoprecipitation experiment also showed the interaction between Creg and TAK1 (Supporting Information Fig. S1 ). Expectedly, Creg inhibited the phosphorylation of TAK1 in a dose-dependent manner (Fig. 7C) . The inhibitory effect of Creg on TAK1 was further supported by primary hepatocytes from Creg ΔHep and Creg-HTG mice, which were challenged by H/R insult (Fig. 7D ). To further demonstrate the interaction domains of Creg and TAK1, a series of deletion mutants of HA-Creg and FLAG-TAK1 were generated (Fig. 7E,F) . Co-immunoprecipitation studies demonstrated that the C-terminal region spanning amino acids 137-220 of Creg [HA-Creg(137-220]) and the N-terminal region spanning the first 300 amino acids of TAK1 (FLAG-TAK1[1-300]) were the interaction regions of Creg and TAK1, respectively (Fig. 7E,F) .
Creg IN HepatoCyteS SUppReSSeS taK1 aCtIVatIoN to ReSCUe HepatIC I/R INJURy
To further confirm the importance of the Creg-TAK1 interaction for Creg function in I/R-induced damage, hepatocytes were infected with an adenoviral vector expressing full-length Creg (Ad-Creg) or truncated Creg (Creg (1-137) , and Ad-Creg-M), in which the TAK1-binding domain of Creg was specifically removed. Subsequently, the protective effect of Creg in hepatocytes subjected to hypoxia challenge was abolished when the hepatocytes were infected with truncated Creg, as evidenced by the phosphorylation levels of related NF-κB and MAPK signaling molecules (Fig. 8A) . In addition, the pro-inflammatory factors and cytokines levels were measured when the hepatocytes were infected with Ad-green fluorescent protein (GFP), Ad-Creg or Ad-Creg-M, followed by hypoxia challenge, and these results showed that the decreased mRNA or medium expression levels of pro-inflammatory factors (TNF-α, IL-1β, IL-6, MCP-1, and CXCL-1), anti-apoptotic gene Bcl2, and increased apoptotic gene Bax and cell proliferation gene PCNA in hepatocytes infected with Ad-Creg were not enhanced but reversed by Ad-Creg-M infection (Fig. 8B,C) . Furthermore, Ad-Creg-M (Creg ) infection failed to promote hepatocyte proliferation, as assessed using MTT assays, or ameliorated LDH release in hepatocytes challenged by H/R treatment, which contrasted with the results obtained with Ad-Creg infection (Fig. 8D,E) . These observations indicated that Creg rescues hepatic I/R injury by binding to TAK1 and suppressing TAK1 activation. 
Discussion
Hepatic I/R injury is a pathological state initiated by a limited blood supply to the liver followed by the subsequent restoration of perfusion and reoxygenation. (5) In the present study, the mRNA and protein expression of Creg was decreased during liver I/R injury. Using genetic approaches, Creg was shown to be a protective factor during hepatic I/R injury. Hepatocyte-specific Creg overexpression showed alleviating effects on cell death and inflammation in the liver, whereas hepatocyte-specific Creg deficiency accelerated I/R-elicited liver damage. Further molecular research demonstrated that Creg physically binds The protein levels of p/t-TAK1, p-JNK1/2, p-p38, IκBα, and p-p65 in the treated cells were measured by western blot (representative of three independent experiments). The mRNA levels (B) and medium levels (C) of pro-inflammatory cytokines and chemokines were measured in the indicated groups (representative of four independent experiments). MTT assays (D) and LDH release (E) of hepatocytes isolated from the indicated groups challenged by H/R treatment (representative of four independent experiments; *P < 0.05 compared with GFP H/R 12h; #P < 0.05 compared with Creg H/R 12 hours). For (A) and (B), Gapdh/β-actin served as the loading control. All data are presented as the mean ± SD. For statistical analysis, one-way ANOVA with Bonferroni's post hoc analysis or Tamhane's T2 post hoc analysis was used. to TAK1 and inhibits the phosphorylation of TAK1 and activation of NF-κB and JNK signaling. More importantly, using a specific TAK1 inhibitor, the destructive effects of Creg deficiency in I/R-related liver injury was reversed, indicating that Creg rescues hepatic I/R injury by suppressing TAK1 activation. The decrease of Creg during the liver I/R injury indicated the possible function during the pathological process. We speculate that the possible molecular mechanism of Creg decrease in I/R injury may be histone modifications directed by DNA methylation, ncRNA, or DNA-binding protein. Another possible reason is that repressors bind to the operator of Creg, coding sequences on the DNA strand that are close to or overlapping the promoter region of Creg, impeding RNA polymerase's progress along the strand, thus impeding the expression of Creg. However, the exact mechanism needs to be further determined.
Cell death has been considered to be one of the hallmarks of I/R injury. Previous studies have shown that knockdown of Creg increased the high glucose/ high palmitate-induced cell apoptosis in human umbilical vein endothelial cells. (27) In addition, Creg overexpression inhibited TNF-α-induced apoptosis through nuclear translocation of NF-κB in mesenchymal stem cells. (28) In addition to cell death, inflammation is another key contributor to I/R injury. The inflammatory response is usually correlated with cellular death in I/R liver injury. Pro-inflammatory signals, such as chemokines, cytokines, reactive oxygen species, and lipid messengers, result in the cell death of hepatocytes. (29) Consequently, cell death releases damage-associated molecular patterns to trigger inflammatory responses. (29) Several studies have also shown that Creg suppressed inflammation and apoptosis by activating PI3K/Akt signaling and inhibiting MARK/p38 signaling of induced pluripotent stem cells in transplantation therapy for myocardial infarction. (25) Consistent with previous findings, in our present study, Creg suppresses cellular death and inflammation during I/R-induced liver injury.
MAPK signaling plays profound biological roles, including inflammation, cell-cycle regulation and cell death, (30) and is widely established to be involved in the progression of hepatic I/R injury. (26, 31, 32) Importantly, Creg has been reported to function in regulating MAPK signaling. Previous studies have demonstrated that Creg blocked MAPK activation and inhibits the apoptosis of human vascular smooth muscle cells. (13) In addition, Creg suppressed inflammation and apoptosis of induced pluripotent stem cells through blocking p38 MARK signaling. (25) However, how Creg fine-tunes the inhibition of MARK signaling still remains unknown. The current study showed that Creg protected against I/R-elicited liver damage by suppressing the activation of MAPK signaling. More importantly, we found that TAK1 is a molecular target during the modulation of Creg during liver I/R injury. In the present study, we demonstrated that Creg physically interacted with TAK1 through specific binding domains and then inhibited TAK1 phosphorylation to rescue hepatic I/R injury.
TAK1 acts as a key regulator of MAPK activation, mediating cellular death and inflammatory responses in a cell-dependent and stimulus-dependent manner. (33, 34) Hepatocyte-specific Tak1-deficient mice leads to spontaneous hepatocyte death, compensatory proliferation, and inflammatory cell infiltration. (17) Interestingly, other studies have revealed that dampening TAK1 could play a protective role in hepatocytes during I/R injury, (26, 35) which are consistent with our results. Consequently, TAK1 might function as a key mediator during the process of hepatic I/R injury and needs to be maintained at a balanced level to support its functional performances in a physiological manner. Furthermore, the distinct partners of TAK1 and their different biological activities are responsible for its dual roles. Our present study demonstrated that Creg interacted with the N-terminal domain of TAK1, which contains the TAB1-binding region and kinase domain, (34) indicating that TAB1 or the modification site might be involved in Creg-regulated hepatic I/R injury. Further experiments demonstrated that the protective function of Creg depends primarily on the inhibition of TAK1 phosphorylation. Collectively, the Creg-TAK1 interaction is essential for Cregmodulated liver I/R insult, and the Creg-TAK1 axis is a promising therapeutic target for the treatment of these pathological conditions.
In conclusion, our current study presents an effect of hepatocyte Creg on liver I/R injury, revealing how Creg-TAK1 interaction lowers the phosphorylation of TAK1 and decreases the activation of MAPK signaling, which protects against cell death and inflammation during the progression of liver I/R injury. Thus, targeting Creg or modulating the Creg-TAK1 interaction may provide a promising therapeutic approach for liver I/R injury.
